Atara Biotherapeutics closed out 2020 by hitting multiple developmental milestones, a $175 million stock offering and a collaboration worth nearly $700 million with Bayer for the development of off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,